An international research team led by Umeå University has made a groundbreaking discovery in the fight against prostate cancer.
The study, published in Molecular Cancer, reveals that activating, rather than blocking, the protein GP130 and its signaling pathway could be a new approach to treating aggressive forms of the disease. This finding challenges previous assumptions and offers hope for patients who currently have limited treatment options.

GP130, or glycoprotein 130, is a receptor found on the surface of cells. When activated, it triggers a signaling pathway within the cell that influences gene expression. A key molecule in this pathway is STAT3, a transcription factor that acts as a switch, turning genes on or off, and impacting cell behavior. STAT3 is known to play a crucial role in the development and spread of tumor cells.

Previous research focused on blocking GP130 and its associated signaling pathway to inhibit STAT3 activity and, consequently, suppress tumor growth. However, this new study demonstrates the opposite effect. Researchers activated GP130 in genetically modified mice and observed a significant slowdown in tumor growth due to the activation of STAT3. These findings were further supported by studies of tissue samples from prostate cancer patients, where high levels of GP130 were linked to better survival rates.
By activating the GP130 signaling pathway, not only is tumor growth slowed, but the immune system is also stimulated to fight the cancer cells.
While further research is needed before this approach can be tested in clinical trials, this study marks a significant step forward in our understanding of prostate cancer and offers hope for new and effective treatments in the future.

Source.